Akers Biosciences, Inc. (AKER) is an interesting player in the Healthcare space, with a focus on Medical Instruments & Supplies. The stock has been active on the tape, currently trading at $0.46, down from yesterday’s close by -2.77%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.Fundamental Analysis
Akers Biosciences, Inc. (AKER) currently trades with a market capitalization of $40.28 Million. That value represents a market adjusting for revenues that have been growing by 112.58 % on a quarterly year/year basis as of the company’s last quarterly report.
You can get a sense of how sustainable that is by a levered free cash flow of -$5.13 Million over the past twelve months. Generally speaking, earnings are expected to hold steady in coming quarters. Analysts are forecasting earnings of $0 on a per share basis this quarter. Perhaps, that suggests something about why 2.73% of the outstanding share supply is held by institutional investors.
We’ve taken a serious look at this stock from a fundamental perspective, but the tale of the tape may offer more hints about what lies under the surface. Looking at the stock’s movement on the chart, Akers Biosciences, Inc. recorded a 52-week high of $1.82. It is now trading 1.36% off that level. The stock is trading $0.63 its 50-day moving average by 0.17%. The stock carved out a 52-week low down at $0.12.
In recent action, Akers Biosciences, Inc. (AKER) has made a move of -18.29% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 12.84, and it’s gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 12.27% with $86.99 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of AKER.